2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Farydak: new trials by email Literature Review of Farydak trials Research Report on Farydak
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Chemosensitivity Assay, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | University of Washington | 9 | 2018-02-08 | 2022-05-09 |
| A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) Revlimid, Velcade, dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Novartis Pharmaceuticals | 6 | 2016-06-14 | 2018-07-24 |
Multiple Myeloma (2)
Novartis Pharmaceuticals (1) · University of Washington (1)
United States (2)
Andrew Cowan (1)
P30CA015704 (1)